Developer docs
API playgroundTry for free, no card

Search company profiles

Destiny Pharma

Full company profile

uuid00044o2

Namestring
Destiny Pharma
Legal namestring
Destiny Pharma plc
Company typeenum
Public
Founded yearint
1997
Descriptiontext

Destiny Pharma plc is a UK-based, publicly traded clinical-stage biotechnology company listed on AIM (ticker: DEST), headquartered in Brighton and founded in 1996. The company develops novel anti-infective drugs targeting drug-resistant bacterial infections, with its primary asset being XF-73, a proprietary drug candidate under investigation for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Since July 2022, XF-73 development has included a cystic fibrosis-focused sub-program supported by a Cystic Fibrosis Foundation award, using clinical isolates from CF patients to assess real-world effectiveness against MRSA — a population with elevated infection risk.

The company's core technology is XF-73 itself, positioned as a novel-method anti-infective compound in a competitive anti-MRSA landscape that includes over 25 active companies developing more than 27 pipeline therapies. There is no evidence of in-licensed platform technology, combination products, or a broader pipeline beyond XF-73 in the available data. The small headcount (11–50 employees) and focus on a single asset is consistent with a single-asset clinical developer.

As a clinical-stage biopharmaceutical, Destiny Pharma does not generate product revenue. Capital has historically been sourced through AIM-listed equity financings and venture rounds, with named investors including Longbow Capital (2008), ACF Investors and Juno Capital Partners (2014), China Medical System Holdings and Downing Ventures (2017), CMS Medical Venture Investment and Downing LLP (2017), and an Antimicrobial Resistance-linked 2019 round. The most recent capital event (March 2023) raised approximately £7.34 million (~$8.89 million) via ~20.96 million new shares, bringing total issued shares to ~94.46 million. Upon any future regulatory approval, commercial distribution would likely proceed through established pharmaceutical supply chains and specialty pharmacy networks, though no commercial GTM motion is currently in place.

Short descriptiontext

Destiny Pharma plc is a UK-based, AIM-listed clinical-stage biopharmaceutical company developing XF-73, a proprietary anti-infective drug candidate for MRSA infections, with a focused expansion into cystic fibrosis patients via a Cystic Fibrosis Foundation-supported program.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBrighton, United Kingdom
HQ citystring
Brighton
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
antimicrobial drug development, clinical-stage biopharmaceuticals, MRSA infection treatment, cystic fibrosis therapeutics, anti-infective pharmaceuticals
Industry1 code
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Anti-infective Pharmaceuticals
Social media profiles2 records
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Destiny Pharma plc is a clinical-stage biopharmaceutical company developing novel antimicrobial drugs, with its lead candidate XF-73 designed for nasal decolonization of methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis patients. The company focuses on developing anti-resistance therapies to address drug-resistant bacterial infections. Founded in 1996 and headquartered in Brighton, UK, the company operates with 11–50 employees.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • XF-73 drug candidate under investigation for MRSA treatment in cystic fibrosis patients through clinical isolate studies
Product overview1 text field

Destiny Pharma is a clinical-stage biotechnology company focused on developing novel anti-infective drugs. The company's primary product candidate is XF-73, a drug being investigated for the treatment of MRSA infections in cystic fibrosis patients, with research supported by the Cystic Fibrosis Foundation. The company operates in the biotechnology/pharmaceutical sector developing drug candidates rather than software products or platforms.

Product and service1 record
1XF-73
CategoryAnti-infective Pharmaceuticals
Description

XF-73 is Destiny Pharma's lead clinical-stage drug candidate — a porphyrin-based novel antimicrobial — designed for nasal decolonization of methicillin-resistant Staphylococcus aureus (MRSA) in patients with cystic fibrosis. It targets the hospital-acquired infection and antimicrobial resistance market.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Nabriva Therapeutics
TypeDirect peer
Description

Develops Xenleta (lefamulin), an antibiotic for community-acquired bacterial pneumonia. Comparable small-cap anti-infective company with similar regulatory pathway and MRSA-adjacent positioning.

TypeEmerging player
Description

Develops direct lytic agents and other therapies for serious infections including MRSA. Comparable as a clinical-stage anti-infective company focused on resistant bacterial infections.

TypeEmerging player
Description

UK-based clinical-stage biotech developing anti-infective therapies including ridinilazole for C. difficile. Comparable as a UK-listed small-cap anti-infective developer with similar operational profile.

TypeRegional player
Description

UK-based clinical-stage company developing antibiotic resistance breakers to potentiate existing antibiotics. Comparable as a UK-based clinical-stage anti-infective developer addressing the same AMR challenge.

TypeDirect peer
Description

Developed iclaprim, an antibiotic targeting MRSA and other Gram-positive infections. Closely comparable small-cap clinical-stage anti-MRSA developer with similar profile to Destiny's XF-73 program.

TypeDirect peer
Description

Markets Baxdela (delafloxacin), an antibiotic approved for acute bacterial skin and skin-structure infections including MRSA. Comparable as a small-cap anti-infective commercial-stage company focused on resistant Gram-positive infections.

TypeDirect peer
Description

Develops Nuzyra (omadacycline), an FDA-approved antibiotic with MRSA activity. Direct competitor in the anti-infective space targeting similar resistant-infection indications, with overlapping commercial and regulatory pathway.

TypeDirect peer
Description

Clinical-stage company developing oral antibiotics (sulopenem) for resistant infections including MRSA. Comparable as a small-cap, single-asset anti-infective developer at similar clinical stage.

TypeEmerging player
Description

Swiss clinical-stage company developing small-molecule anti-infectives addressing antimicrobial resistance. Comparable as a small-cap clinical-stage AMR-focused developer with similar therapeutic approach.

TypeBroad incumbent
Description

Developed Xerava (eravacycline), a fluorocycline antibiotic approved for complicated intra-abdominal infections. Comparable as an anti-infective commercial-stage peer acquired by La Jolla Pharmaceutical, illustrating the small-cap anti-infective M&A pathway available to Destiny.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Destiny Pharma

Anti-infective Pharmaceuticalsdestinypharma.com

Destiny Pharma plc is a UK-based, AIM-listed clinical-stage biopharmaceutical company developing XF-73, a proprietary anti-infective drug candidate for MRSA infections, with a focused expansion into cystic fibrosis patients via a Cystic Fibrosis Foundation-supported program.

What Destiny Pharma does

Destiny Pharma plc is a UK-based, publicly traded clinical-stage biotechnology company listed on AIM (ticker: DEST), headquartered in Brighton and founded in 1996. The company develops novel anti-infective drugs targeting drug-resistant bacterial infections, with its primary asset being XF-73, a proprietary drug candidate under investigation for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Since July 2022, XF-73 development has included a cystic fibrosis-focused sub-program supported by a Cystic Fibrosis Foundation award, using clinical isolates from CF patients to assess real-world effectiveness against MRSA — a population with elevated infection risk.

The company's core technology is XF-73 itself, positioned as a novel-method anti-infective compound in a competitive anti-MRSA landscape that includes over 25 active companies developing more than 27 pipeline therapies. There is no evidence of in-licensed platform technology, combination products, or a broader pipeline beyond XF-73 in the available data. The small headcount (11–50 employees) and focus on a single asset is consistent with a single-asset clinical developer.

As a clinical-stage biopharmaceutical, Destiny Pharma does not generate product revenue. Capital has historically been sourced through AIM-listed equity financings and venture rounds, with named investors including Longbow Capital (2008), ACF Investors and Juno Capital Partners (2014), China Medical System Holdings and Downing Ventures (2017), CMS Medical Venture Investment and Downing LLP (2017), and an Antimicrobial Resistance-linked 2019 round. The most recent capital event (March 2023) raised approximately £7.34 million (~$8.89 million) via ~20.96 million new shares, bringing total issued shares to ~94.46 million. Upon any future regulatory approval, commercial distribution would likely proceed through established pharmaceutical supply chains and specialty pharmacy networks, though no commercial GTM motion is currently in place.

Destiny Pharma firmographics

Firmographics
Name
Destiny Pharma
Legal name
Destiny Pharma plc
Website
https://destinypharma.com
Company type
Public
Founded year
1997
Operating status
Operating
Headcount range
1–10 employees
Short description
Destiny Pharma plc is a UK-based, AIM-listed clinical-stage biopharmaceutical company developing XF-73, a proprietary anti-infective drug candidate for MRSA infections, with a focused expansion into cystic fibrosis patients via a Cystic Fibrosis Foundation-supported program.
Ownership category
akta.pro rank

Destiny Pharma industry classification

Industry
Product category
Anti-infective Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Antimicrobial drug development
  • Clinical-stage biopharmaceuticals
  • MRSA infection treatment
  • Cystic fibrosis therapeutics
  • Anti-infective pharmaceuticals

Where Destiny Pharma is headquartered

Location

Headquarters

HQ city
Brighton
HQ country
United Kingdom
HQ region
Europe

Markets served

Destiny Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Destiny Pharma product offering

Product offering

Core offering

Destiny Pharma plc is a clinical-stage biopharmaceutical company developing novel antimicrobial drugs, with its lead candidate XF-73 designed for nasal decolonization of methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis patients. The company focuses on developing anti-resistance therapies to address drug-resistant bacterial infections. Founded in 1996 and headquartered in Brighton, UK, the company operates with 11–50 employees.

Product overview

Destiny Pharma is a clinical-stage biotechnology company focused on developing novel anti-infective drugs. The company's primary product candidate is XF-73, a drug being investigated for the treatment of MRSA infections in cystic fibrosis patients, with research supported by the Cystic Fibrosis Foundation. The company operates in the biotechnology/pharmaceutical sector developing drug candidates rather than software products or platforms.

Differentiator

Problem solved

Functional benefit

Products and services

  • XF-73 XF-73 is Destiny Pharma's lead clinical-stage drug candidate — a porphyrin-based novel antimicrobial — designed for nasal decolonization of methicillin-resistant Staphylococcus aureus (MRSA) in patients with cystic fibrosis. It targets the hospital-acquired infection and antimicrobial resistance market.

Quantifiable outcome

  • XF-73 drug candidate under investigation for MRSA treatment in cystic fibrosis patients through clinical isolate studies

Companies that use Destiny Pharma

Customer profile

Segments1 record

Ideal customer profiles1 record

Destiny Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Destiny Pharma partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Destiny Pharma competitors and assessment

Company assessment

Direct peers

  • Nabriva Therapeutics: Develops Xenleta (lefamulin), an antibiotic for community-acquired bacterial pneumonia. Comparable small-cap anti-infective company with similar regulatory pathway and MRSA-adjacent positioning.
  • Motif Bio: Developed iclaprim, an antibiotic targeting MRSA and other Gram-positive infections. Closely comparable small-cap clinical-stage anti-MRSA developer with similar profile to Destiny's XF-73 program.
  • Melinta Therapeutics: Markets Baxdela (delafloxacin), an antibiotic approved for acute bacterial skin and skin-structure infections including MRSA. Comparable as a small-cap anti-infective commercial-stage company focused on resistant Gram-positive infections.
  • Paratek Pharmaceuticals: Develops Nuzyra (omadacycline), an FDA-approved antibiotic with MRSA activity. Direct competitor in the anti-infective space targeting similar resistant-infection indications, with overlapping commercial and regulatory pathway.
  • Iterum Therapeutics: Clinical-stage company developing oral antibiotics (sulopenem) for resistant infections including MRSA. Comparable as a small-cap, single-asset anti-infective developer at similar clinical stage.

Emerging players

  • ContraFect Corporation: Develops direct lytic agents and other therapies for serious infections including MRSA. Comparable as a clinical-stage anti-infective company focused on resistant bacterial infections.
  • Summit Therapeutics: UK-based clinical-stage biotech developing anti-infective therapies including ridinilazole for C. difficile. Comparable as a UK-listed small-cap anti-infective developer with similar operational profile.
  • BioVersys: Swiss clinical-stage company developing small-molecule anti-infectives addressing antimicrobial resistance. Comparable as a small-cap clinical-stage AMR-focused developer with similar therapeutic approach.

Regional players

  • Helperby Therapeutics: UK-based clinical-stage company developing antibiotic resistance breakers to potentiate existing antibiotics. Comparable as a UK-based clinical-stage anti-infective developer addressing the same AMR challenge.

Broad incumbents

  • Tetraphase Biosciences: Developed Xerava (eravacycline), a fluorocycline antibiotic approved for complicated intra-abdominal infections. Comparable as an anti-infective commercial-stage peer acquired by La Jolla Pharmaceutical, illustrating the small-cap anti-infective M&A pathway available to Destiny.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Destiny Pharma social profiles

Digital presence

Destiny Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Destiny Pharma leadership team

Management profile

Number of profiles

Profiles5 records

Destiny Pharma funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Destiny Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Destiny Pharma

What does Destiny Pharma do?

Destiny Pharma plc is a clinical-stage biopharmaceutical company developing novel antimicrobial drugs, with its lead candidate XF-73 designed for nasal decolonization of methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis patients. The company focuses on developing anti-resistance therapies to address drug-resistant bacterial infections. Founded in 1996 and headquartered in Brighton, UK, the company operates with 11–50 employees.

Is Destiny Pharma a public or private company?

Destiny Pharma is a public company. It is classified as public and is currently operating.

When was Destiny Pharma founded?

Destiny Pharma was founded in 1997. It employs 1 to 10 people.

Where is Destiny Pharma based?

Destiny Pharma is headquartered in Brighton, United Kingdom, in the Europe region.

Who are Destiny Pharma's main competitors?

Direct peers on record are Nabriva Therapeutics, Motif Bio, Melinta Therapeutics, Paratek Pharmaceuticals and Iterum Therapeutics. Emerging players are ContraFect Corporation, Summit Therapeutics and BioVersys. Helperby Therapeutics is listed as a regional player. Tetraphase Biosciences is listed as a broad incumbent.

Does Destiny Pharma have an API?

No public API is recorded for Destiny Pharma.

What industry is Destiny Pharma in?

Destiny Pharma's product category is Anti-infective Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmiWeb.comDestiny Pharma Awarded Innovation Passport Designation by the UK MHRA for XF-73 Nasal for the Prevention of Post-Surgical Site InfectionsThe UK MHRA granted an Innovation Passport to Destiny Pharma's XF-73 Nasal for preventing post-surgical site infections, enabling access to the Innovative Licensing and Access Pathway. The drug is potent against all MRSA strains and is Phase 3 ready. The company will collaborate with ILAP to accelerate development and patient access.DestinypharmaResult of General Meeting and Total Voting RightsDestiny Pharma plc announced that all resolutions proposed at its General Meeting were passed by shareholders, enabling the company to raise approximately £7.34 million in gross proceeds. The company has allotted 20,961,956 new shares, with admission of these shares expected to occur on 17 March 2023.ZapierDestiny Pharma receives award from the Cystic Fibrosis FoundationDestiny Pharma has received an award from the Cystic Fibrosis Foundation to investigate the potential of its proprietary drug XF-73 as a treatment for MRSA infections in cystic fibrosis patients. The research project will utilize clinical isolates collected by the Foundation to evaluate the drug's efficacy against antibiotic-resistant bacteria. Financial terms of this collaboration were not disclosed.Finance Monthly Fintech Awards 2023Why Innovation in MedTech is a Driver of New Investment Opportunities - Finance MonthlyJuno Capital partner Edward Rudd highlights medical technology as a key driver for investment, citing the company's continued backing of Sky Medical Technology and its geko™ wearable device. The article details how Juno also invested in Destiny Pharma to develop anti-infective drugs, emphasizing that platform technologies with strong clinical data offer lower regulatory risk and higher potential returns.The Pharma LetterDestiny soars on new data for XF-73 Nasal GelDestiny Pharma announced positive top-line results from its Phase IIb study of XF-73 nasal gel for preventing post-surgical MRSA infections. The primary efficacy endpoint was met with high statistical significance and no treatment-related safety events.GlobeNewswireEdison issues initiation on Destiny Pharma (DEST)Edison issued an initiation on Destiny Pharma, valuing the company at £89.1m or £2.04 per share based on XF-73 for post-surgical infections. Edison forecasts Destiny's cash reach to at least 2020, with Phase IIb results expected by end of 2019. The company may enter a global licensing transaction on XF-73 as soon as 2020.FinSMEsDestiny Pharma Receives £2.8M in FundingDestiny Pharma, a UK-based pharmaceutical company, received £2.8m in funding from Angel CoFund and other UK investors. The funds will support a clinical trial for its lead drug XF-73, which aims to prevent post-surgical Staphylococcal infections. The company plans to globally commercialize candidates from its XF Drug platform.